Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception.
about
Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve MarkersIndividualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practiceFertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessmentFollicle stimulating hormone and anti-Müllerian hormone per oocyte in predicting in vitro fertilization pregnancy in high responders: a cohort studyWhich cut-off value of serum anti-Müllerian hormone level can predict poor ovarian reserve, poor ovarian response to stimulation and in vitro fertilization success? A prospective data analysis.The Effect of Moderate Physical Activity on Ovarian Reserve Markers in Reproductive Age Women Below and Above 30 Years.The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropinOxidative Stress Markers in GnRH Agonist and Antagonist Protocols in IVF.Biological variability in serum anti-Müllerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women.Can egg donor selection be improved?--A pilot studyAnti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization.The role of anti-Müllerian hormone in female fertility and infertility - an overview.Efficacy of dehydroepiandrosterone to overcome the effect of ovarian ageing (DITTO): a proof of principle randomised controlled trial protocol.Comparing serum basal and follicular fluid levels of anti-Müllerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome.The physiology and clinical utility of anti-Mullerian hormone in women.The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature.The use of ovarian reserve markers in IVF clinical practice: a national consensus.Testing for Ovarian Reserve in Assisted Reproduction programs: the current point of view.Ongoing pregnancy rates in women with low and extremely low AMH levels. A multivariate analysis of 769 cycles.Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients.Serum dehydroepiandrosterone sulphate concentration is not a predictive factor in IVF outcomes before the first cycle of GnRH agonist administration in women with normal ovarian reserve.Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatmentAnti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone.Single nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile(49)Ser) and Anti-Müllerian hormone type II receptor (AMHRII -482 A>G) as genetic markers in assisted reproduction technology.Different ART outcomes at increasing peak estradiol levels with long and antagonist protocols: retrospective insights from ten years experience.Serum anti-Müllerian hormone as a predictive marker of polycystic ovarian syndrome.Different ovarian response by age in an anti-Müllerian hormone-matched group undergoing in vitro fertilization.Ovarian reserve testsWhat is the value of anti-Müllerian hormone in predicting the response to ovarian stimulation with GnRH agonist and antagonist protocols?Serum anti-Müllerian hormone is a better predictor of ovarian response than FSH and age in IVF patients with endometriosis.Circulating LH/hCG receptor (LHCGR) may identify pre-treatment IVF patients at risk of OHSS and poor implantation.Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols.Ovarian reserve assessment for infertility investigation.The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments.Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism.Primary ovarian insufficiency in classic galactosemia: role of FSH dysfunction and timing of the lesion.Clinical application of anti-Müllerian hormone as a predictor of controlled ovarian hyperstimulation outcomeThe anti mullerian hormone- a novel marker for assessing the ovarian reserve in women with regular menstrual cyclesA new ovarian response prediction index (ORPI): implications for individualised controlled ovarian stimulationIndividualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count.
P2860
Q26765770-10845B63-44D8-443B-B1DC-C2A9C5965821Q26829747-8709DEDC-3FD5-460E-8BBF-6DC8AF1D0DD3Q28077710-2C2C6203-30F8-4719-8FC6-1B8CC3CA9436Q28730415-89F49119-5144-49EE-AA6D-A69B1DF3C47CQ30766464-2EB57425-C1A8-45FD-A837-9C7CF6908D7FQ33604971-22596184-0ECC-43CE-85DC-D8F7F3922431Q33761614-28299E9E-4A72-4F48-9650-5BD1FEBD1380Q33801073-1A339041-E379-4110-8A9D-39C09D6BC651Q33888297-16ED5CB8-0B22-41AB-8AFA-5B419D684ACBQ33986762-90090370-084D-4124-BFE1-8E5CB05987E6Q34138075-26DC7EB4-488C-4C30-8424-2FEDE8BF9A50Q34278051-E4B9BC2A-5357-42C4-9884-42ABFCE9115CQ34327502-0AE85E4F-42B7-4DA3-AF99-7C2433F3359EQ34363167-B76FBEAC-E880-42F6-9BC9-F830028E46ADQ34398233-46AC6597-8DE4-4E98-B768-D0A14B590A5BQ34404612-3A0F8114-1E8B-439F-93CC-A92018144CF4Q34500365-AE1FB1BD-DC11-4168-957A-E73349D48B56Q34608174-C285BB5E-0863-4BAB-97F1-6EA6F4DDF122Q35074369-9E0A3EF4-DC8A-44B6-83A0-E2D184F11764Q35147438-7FA5D80A-47BB-48F4-A927-74E0F0238FF0Q35148124-1804AA0E-D9C2-44DA-B527-28A8D6D037C0Q35171104-3027B4B8-343B-4C22-BC41-157D6749FFB0Q35181958-0FB74CDC-97F4-4A7D-A0D7-3A809A07257EQ35186943-48027BFB-0A24-4A42-9D32-AEEBD5A42ED3Q35205814-43BD5060-133E-4921-BCC2-3C274D711172Q35560602-D3D4BCFB-D18B-44A2-A355-BCB45B7BD6E0Q35722615-CAAE1D84-6850-4167-ACE1-6D1D98850D15Q35749173-15120B1B-1997-409F-94AE-4EDBE64EF2B7Q35750252-98D5D829-6B9E-4260-B894-2106833A6F65Q35767868-349B4BB9-05DD-4955-A58E-A3C3572A8740Q35774819-6C3DECFF-C7AC-478A-A769-FE182C885216Q35822351-ED1C28D3-B142-4502-B266-7A5206D8E950Q35825844-1E8DEC6F-B934-4262-BF5B-7667679FFCDFQ35976287-91B38106-12DD-445F-B032-3D66D5B5A4BFQ36106370-3D64EE4E-2191-4F3C-A7F3-6109C734DFCDQ36527832-BAD20A46-FDFF-4E75-BA42-DC1649A6EC86Q36542516-489D23E2-370F-4CE2-AE60-786FDD45CFA4Q36554078-DA9AC50D-6590-445C-8065-11A3504DD236Q36594368-614C2C25-A1A7-4A2B-A45B-D1406CD8B043Q36599421-18B37542-A30C-4016-9797-4AEF64123718
P2860
Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Anti-Müllerian hormone-based a ...... ation for assisted conception.
@ast
Anti-Müllerian hormone-based a ...... ation for assisted conception.
@en
Anti-Müllerian hormone-based a ...... ation for assisted conception.
@nl
type
label
Anti-Müllerian hormone-based a ...... ation for assisted conception.
@ast
Anti-Müllerian hormone-based a ...... ation for assisted conception.
@en
Anti-Müllerian hormone-based a ...... ation for assisted conception.
@nl
prefLabel
Anti-Müllerian hormone-based a ...... ation for assisted conception.
@ast
Anti-Müllerian hormone-based a ...... ation for assisted conception.
@en
Anti-Müllerian hormone-based a ...... ation for assisted conception.
@nl
P2093
P356
P1433
P1476
Anti-Müllerian hormone-based a ...... ation for assisted conception.
@en
P2093
Helen Lyall
Isabel Traynor
Marco Gaudoin
Maybeth Jamieson
Pat Ambrose
Paul Mitchell
Richard Fleming
Robin W Yates
P304
P356
10.1093/HUMREP/DEN480
P407
P577
2009-01-10T00:00:00Z